TG Therapeutics' (TGTX) Treatment for Chronic Lymphocytic Leukemia Granted Orphan Status by FDA

August 24, 2016 8:22 AM EDT

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

TG Therapeutics' (NASDAQ: TGTX) treatment for chronic lymphocytic leukemia was granted orphan status by the FDA. The generic name is phosphoinositide-3-kinase delta inhibitor.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, FDA

Add Your Comment